Treatment with Immunosuppressive Therapy May Improve Depressive Symptoms in Patients with Inflammatory Bowel Disease

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 465-470

  Horst, Sara ^a   Chao, Andrew ^a   Rosen, Michael ^b   Nohl, Anne ^a   Duley, Caroline ^a   Wagnon, Julianne H ^a   Beaulieu, Dawn B ^a   Taylor, Warren ^a   Gaines, Lawrence ^a   Schwartz, David A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Anti tumor necrosis factor antibody; Azathioprine; Crohn s disease; Depression; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DSM-IV; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT HEALTH QUESTIONNAIRE 9; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; COMPLICATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; DEPRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84925025925     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3375-0     Document Type: Article

References (33)

1. Addolorato G, Capristo E, Stefanini GF, et al. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol. 1997;32:1013–1021.
2. Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001;55:716–720.
3. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis. 2006;12:697–707.
4. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol. 2008;103:1989–1997.
5. Goodhand JR, Wahed M, Mawdsley JE, et al. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012;18:2301–2309.
6. Loftus EV Jr, Guerin A, Yu AP, et al. Increased risks of developing anxiety and depression in young patients with Crohn’s disease. Am J Gastroenterol. 2011;106:1670–1677.
7. Porcelli P, Leoci C, Guerra V. A prospective study of the relationship between disease activity and psychologic distress in patients with inflammatory bowel disease. Scand J Gastroenterol. 1996;31:792–796.
8. Calvet X, Gallardo O, Coronas R, et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn’s disease. Inflamm Bowel Dis. 2006;12:692–696.
9. Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am J Gastroenterol. 1994;89:1219–1225.
10. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389–396.
11. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15:1105–1118.
12. Ananthakrishnan AN, Gainer VS, Perez RG, et al. Psychiatric co-morbidity is associated with increased risk of surgery in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:445–454.
13. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004;66:79–84.
14. Bonaz BL, Bernstein CN. Brain–gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36–49.
15. Angelopoulos NV, Mantas C, Dalekos GN, et al. Psychiatric factors in patients with ulcerative colitis according to disease activity. Eur J Psychiatry. 1996;10:87–99.
16. Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22:101–110.
17. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn’s disease. Inflamm Bowel Dis. 2002;8:237–243.
18. Minderhoud IM, Samsom M, Oldenburg B. Crohn’s disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol. 2007;13:2089–2093.
19. Guloksuz S, Wichers M, Kenis G, et al. Depressive symptoms in Crohn’s disease: relationship with immune activation and tryptophan availability. PLoS One. 2013;8:e60435.
20. Langhorst J, Hofstetter A, Wolfe F, et al. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. Inflamm Bowel Dis. 2013;19:2380–2386.
21. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488–496.
22. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4:1491–1501.
23. Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:1470–1479.
24. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.
25. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.
26. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613.
27. Nease DE Jr, Maloin JM. Depression screening: a practical strategy. J Fam Pract. 2003;52:118–124.
28. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.
29. Lerebours E, Gower-Rousseau C, Merle V, et al. Stressful life events as a risk factor for inflammatory bowel disease onset: a population-based case–control study. Am J Gastroenterol. 2007;102:122–131.
30. Ertenli I, Ozer S, Kiraz S, et al. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int. 2012;32:323–330.
31. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246.e6–1256.e6.
32. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–186.
33. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.